Home Newsfeeds Wedbush Downgrades Vera Therapeutics to Neutral, Announces $8 Price Target

Wedbush Downgrades Vera Therapeutics to Neutral, Announces $8 Price Target

Wedbush analyst Laura Chico downgrades Vera Therapeutics (NASDAQ:VERA) from Outperform to Neutral and announces $8 price target.

byBenzinga Newsdesk

January 4, 2023

1 minute read

Wedbush analyst Laura Chico downgrades Vera Therapeutics (NASDAQ:VERA) from Outperform to Neutral and announces $8 price target.

Bitcoin, Ethereum, Dogecoin Plummet As FOMC Minutes Reveal Agreement On Rate Hike: Analyst Predicts 2024-2025 As Golden Era For Apex Crypto

By Mehab Qureshi

October 11, 10:47 PM

Major cryptocurrencies experienced a decline on Wednesday evening following the release of the minutes from the September Federal Open Market Committee meeting earlier today. These minutes have revealed that a majority of committ

$DOGE

Telsey Advisory Group Maintains Outperform on Arhaus, Raises Price Target to $12

By Benzinga Newsdesk

August 12, 5:04 AM

Telsey Advisory Group analyst Joseph Feldman maintains Arhaus (NASDAQ:ARHS) with a Outperform and raises the price target from $9 to $12.

ARHS

John Wiley & Sons Q1 Adj. EPS $0.36 Misses $0.67 Estimate, Sales $488.00M Miss $501.60M Estimate

By Bill Haddad

September 7, 7:30 AM

John Wiley & Sons (NYSE:WLY) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.67 by 46.27 percent. This is a 33.33 percent decrease over earnings of $0.54 per share from

WLY